Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WS016 in patients with hyperkalemia
NCT06277128Phase 2Recruiting
- Sponsor
- Waterstone Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Apr 2024
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WS016 in hyperkalemia, sponsored by Waterstone Pharmaceuticals. Started Sep 2023; status: recruiting.
02
Drugs
WS016
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT06277128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277128.